241 related articles for article (PubMed ID: 38338729)
21. The role of Src in solid tumors.
Wheeler DL; Iida M; Dunn EF
Oncologist; 2009 Jul; 14(7):667-78. PubMed ID: 19581523
[TBL] [Abstract][Full Text] [Related]
22. SRC catalytic but not scaffolding function is needed for integrin-regulated tyrosine phosphorylation, cell migration, and cell spreading.
Cary LA; Klinghoffer RA; Sachsenmaier C; Cooper JA
Mol Cell Biol; 2002 Apr; 22(8):2427-40. PubMed ID: 11909938
[TBL] [Abstract][Full Text] [Related]
23. Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells.
Hirsch CL; Smith-Windsor EL; Bonham K
Int J Cancer; 2006 Feb; 118(3):547-54. PubMed ID: 16094635
[TBL] [Abstract][Full Text] [Related]
24. Linkage disequilibrium and haplotype analysis of
Nisar A; Mahjabeen I; Mehmood A; Ahmed MW; Khurshid K; Kayani MA
Future Oncol; 2020 Apr; 16(12):779-792. PubMed ID: 32253932
[No Abstract] [Full Text] [Related]
25. A renaissance for YES in cancer.
Lapouge M; Meloche S
Oncogene; 2023 Nov; 42(46):3385-3393. PubMed ID: 37848624
[TBL] [Abstract][Full Text] [Related]
26. Role of YES1 amplification in EGFR mutation-positive non-small cell lung cancer: Primary resistance to afatinib in a patient.
Tao J; Sun D; Hou H
Thorac Cancer; 2020 Sep; 11(9):2736-2739. PubMed ID: 32744377
[TBL] [Abstract][Full Text] [Related]
27. MiR-17-5p up-regulates YES1 to modulate the cell cycle progression and apoptosis in ovarian cancer cell lines.
Li L; He L; Zhao JL; Xiao J; Liu M; Li X; Tang H
J Cell Biochem; 2015 Jun; 116(6):1050-9. PubMed ID: 25561420
[TBL] [Abstract][Full Text] [Related]
28. miR-133a targets YES1 to reduce cisplatin resistance in ovarian cancer by regulating cell autophagy.
Zhou Y; Wang C; Ding J; Chen Y; Sun Y; Cheng Z
Cancer Cell Int; 2022 Jan; 22(1):15. PubMed ID: 35012539
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer.
Majid S; Saini S; Dar AA; Hirata H; Shahryari V; Tanaka Y; Yamamura S; Ueno K; Zaman MS; Singh K; Chang I; Deng G; Dahiya R
Cancer Res; 2011 Apr; 71(7):2611-21. PubMed ID: 21330408
[TBL] [Abstract][Full Text] [Related]
30. c-Src is required for glial cell line-derived neurotrophic factor (GDNF) family ligand-mediated neuronal survival via a phosphatidylinositol-3 kinase (PI-3K)-dependent pathway.
Encinas M; Tansey MG; Tsui-Pierchala BA; Comella JX; Milbrandt J; Johnson EM
J Neurosci; 2001 Mar; 21(5):1464-72. PubMed ID: 11222636
[TBL] [Abstract][Full Text] [Related]
31. Src kinases as therapeutic targets for cancer.
Kim LC; Song L; Haura EB
Nat Rev Clin Oncol; 2009 Oct; 6(10):587-95. PubMed ID: 19787002
[TBL] [Abstract][Full Text] [Related]
32. Long non-coding TUG1 accelerates prostate cancer progression through regulating miR-128-3p/YES1 axis.
Hao SD; Ma JX; Liu Y; Liu PJ; Qin Y
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):619-632. PubMed ID: 32016963
[TBL] [Abstract][Full Text] [Related]
33. Personalized Cancer Therapy: YES1 Is the New Kid on the Block.
Rai K
Cancer Res; 2019 Nov; 79(22):5702-5703. PubMed ID: 31772072
[TBL] [Abstract][Full Text] [Related]
34. Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling.
Rubbi L; Titz B; Brown L; Galvan E; Komisopoulou E; Chen SS; Low T; Tahmasian M; Skaggs B; Müschen M; Pellegrini M; Graeber TG
Sci Signal; 2011 Mar; 4(166):ra18. PubMed ID: 21447799
[TBL] [Abstract][Full Text] [Related]
35. Activation of the lutropin/choriogonadotropin receptor in MA-10 cells leads to the tyrosine phosphorylation of the focal adhesion kinase by a pathway that involves Src family kinases.
Mizutani T; Shiraishi K; Welsh T; Ascoli M
Mol Endocrinol; 2006 Mar; 20(3):619-30. PubMed ID: 16293639
[TBL] [Abstract][Full Text] [Related]
36. Identification of potent Yes1 kinase inhibitors using a library screening approach.
Patel PR; Sun H; Li SQ; Shen M; Khan J; Thomas CJ; Davis MI
Bioorg Med Chem Lett; 2013 Aug; 23(15):4398-403. PubMed ID: 23787099
[TBL] [Abstract][Full Text] [Related]
37. Circ_0081143 Contributes to Gastric Cancer Malignant Development and Doxorubicin Resistance by Elevating the Expression of YES1 by Targeting mziR-129-2-3p.
Ou W; Lin L; Chen R; Xu Q; Zhou C
Gut Liver; 2022 Nov; 16(6):861-874. PubMed ID: 35686503
[TBL] [Abstract][Full Text] [Related]
38. Src family kinases are required for integrin but not PDGFR signal transduction.
Klinghoffer RA; Sachsenmaier C; Cooper JA; Soriano P
EMBO J; 1999 May; 18(9):2459-71. PubMed ID: 10228160
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
[TBL] [Abstract][Full Text] [Related]
40. Csk-homologous kinase (Chk) is an efficient inhibitor of Src-family kinases but a poor catalyst of phosphorylation of their C-terminal regulatory tyrosine.
Advani G; Lim YC; Catimel B; Lio DSS; Ng NLY; Chüeh AC; Tran M; Anasir MI; Verkade H; Zhu HJ; Turk BE; Smithgall TE; Ang CS; Griffin M; Cheng HC
Cell Commun Signal; 2017 Aug; 15(1):29. PubMed ID: 28784162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
